[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575504":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":65,"collaborators":26,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"esketamine group","EXPERIMENTAL","After the patient is induced with general anesthesia, esketamine (0.3 mg\u002Fkg\u002Fh) will be continuously infused during the operation until the end of the operation.",[13],"Drug: Esketamine at low dose",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","PLACEBO_COMPARATOR","After the patient's general anesthesia induction is completed, normal saline will be continuously infused until the end of the operation, and the infusion volume is the same as that of the esketamine group.",[19],"Other: Normal Saline (0.9% NaCl)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Esketamine at low dose","After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg\u002Fkg\u002Fh) until the end of the operation.",[9],null,{"type":6,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Normal Saline (0.9% NaCl)",[15],[31],{"name":32,"affiliation":33,"role":34},"xiaoliang wang","The First Affiliated Hospital with Nanjing Medical University","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"wenwen zhang, Dr","CONTACT","+8615366110306","1395626955@qq.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Nanjing First Hospital","RECRUITING","Nanjing","Jiangsu","210006","China","CN",{"type":51,"coordinates":52},"Point",[53,54],118.77778,32.06167,{"lat":54,"lon":53},[57,61,62],{"name":58,"role":38,"phone":59,"phoneExt":26,"email":60},"zhang ying, Master degree","86+15380998716","1070434273@qq.com",{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":63,"role":64,"phone":26,"phoneExt":26,"email":26},"wang xiao liang, Dr","PRINCIPAL_INVESTIGATOR",{"type":66,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100575504","effect-of-subanesthetic-dose-of-esketamine-on-sleep-quality-100575504",false,"NCT06773143","Effect of Subanesthetic Dose of Esketamine on Sleep Quality","Effect of Subanesthetic Dose of Esketamine on Sleep Quality in Patients With Breast Cancer After Chemotherapy","EOSDOEOSQ","Inclusion Criteria:\n\n1. Patients diagnosed with breast cancer by pathology and immunohistochemistry\n2. Patients receiving neoadjuvant chemotherapy\n3. Age 18 to 65 years old; d) ;\n4. ASA grade Ⅰ - Ⅲ\n5. BMI 18 to 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* 1: Patients refuse to participate in the study\n\n  2: BMI \\> 30 kg\u002Fm2\n\n  3: Recent history of drug abuse\n\n  4: Allergy to or contraindications to esketamine\n\n  5: Cognitive dysfunction or inability to communicate\n\n  6: Severe dysfunction of important organs such as liver and kidney function","FEMALE","18 Years","65 Years",{"count":79,"type":80},184,"ESTIMATED","INTERVENTIONAL",[83],"NA","The goal of this clinical trial is to explore whether subanesthetic doses of esketamine can improve the sleep quality of patients undergoing modified radical mastectomy for breast cancer. In this study, 184 people are expected to participate from admission to three days after surgery.\n\nThe process requires participants to cooperate with the completion of the digital rating scale, the Athens Insomnia Scale, the Visual Analog Pain Rating Scale, the Hospital Anxiety and Depression Rating Scale, and the collection of venous blood for research indicators (IL-6, TNF-α, cor, BDNF).\n\nIf participants agree to participate in this study, the investigators will assign a unique identification number to each participant and create a medical record for participants.\n\nOne day before surgery, the investigators will conduct assessments using the Athens Insomnia Scale, the Visual Analog Pain Rating Scale, and the Hospital Anxiety and Depression Scale, and collect approximately 6 mL of venous blood.\n\nOne day after surgery, the investigators will repeat the assessments using the Athens Insomnia Scale, the Visual Analog Pain Rating Scale, and the Hospital Anxiety and Depression Scale. Additionally, the investigators will collect another 6 mL of venous blood and monitor the use of analgesics.\n\nThe investigators will follow up with participants three days after the surgery. During this follow-up, investigators will assess any sleep disturbances, administer the Hospital Anxiety and Depression Scale, and review the use of analgesics.",[86,87,88],"Insomnia","Breast Cancer Surgery","Esketamine","2025-02-06",{"date":91,"type":92},"2025-02-10","ACTUAL",{"date":94,"type":92},"2024-12-30",{"date":96,"type":80},"2027-04-30",{"name":5,"class":6},1]